ARTICLE | Clinical News
Fampridine-SR: Began Phase II trial
December 4, 2000 8:00 AM UTC
Acorda Therapeutics Inc., Hawthorne, N.Y. Product: Fampridine-SR Business: Neurological Therapeutic category: Neurotransmission, Ion channel modulation Target: Neuronal potassium channels Description...